Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yabao Pharmaceutical Group CoSHSE:600351 -3.53%70 Altman Z2-Score is 10.61 as of Jul. 18, 2026, which is 130% above its 10-year median of 4.62. GuruFocus rates SHSE:600351 with a GF Score™ of 70/100 and a GF Value™ of ¥5.53 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 997 Drug Manufacturers companies, Yabao Pharmaceutical Group Co ranks better than 87.66% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Yabao Pharmaceutical Group Co has a Altman Z2-Score of 10.61, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Yabao Pharmaceutical Group Co's Altman Z2-Score or its related term are showing as below:
SHSE:600351'
s Altman Z2-Score Range Over the Past 10 Years
Min: 2.67 Med: 4.62 Max: 11.03
Current: 10.61
During the past 13 years, Yabao Pharmaceutical Group Co's highest Altman Z2-Score was 11.03. The lowest was 2.67. And the median was 4.62.
Yabao Pharmaceutical Group Co (SHSE:600351) Altman Z2-Score Explanation
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yabao Pharmaceutical Group Co Altman Z2-Score Chart
SHSE:600351 vs ZTS, UTHR: Altman Z2-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Yabao Pharmaceutical Group Co's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yabao Pharmaceutical Group Co Altman Z2-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Yabao Pharmaceutical Group Co's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Yabao Pharmaceutical Group Co's Altman Z2-Score falls into.
Yabao Pharmaceutical Group Co Altman Z2-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Yabao Pharmaceutical Group Co (SHSE:600351) has a Altman Z2-Score of 10.61 as of Jul. 18, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Yabao Pharmaceutical Group Co and its competitors. This is 130% above median its historical median of 4.62. Over the past decade, Yabao Pharmaceutical Group Co's Altman Z2-Score has ranged from 2.67 to 11.03. According to the industry distribution chart, Yabao Pharmaceutical Group Co ranks #123 out of 997 companies in the Drug Manufacturers industry, placing it in the top 12.3%.
Is Yabao Pharmaceutical Group Co's Altman Z2-Score too high?
Yabao Pharmaceutical Group Co's current Altman Z2-Score of 10.61 is 130% above median its 10-year median of 4.62. Over the past 10 years, this metric has ranged from a low of 2.67 to a high of 11.03. The Drug Manufacturers industry median Altman Z2-Score is 3.88. Yabao Pharmaceutical Group Co's value of 10.61 is 173.5% above this industry median. Based on the distribution chart, Yabao Pharmaceutical Group Co ranks #123 out of 997 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Yabao Pharmaceutical Group Co has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Yabao Pharmaceutical Group Co's Altman Z2-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Yabao Pharmaceutical Group Co ranks #123 out of 997 companies for Altman Z2-Score. This places Yabao Pharmaceutical Group Co in the top 12% of its industry — outperforming the majority of peers. The industry median Altman Z2-Score is 3.88. Yabao Pharmaceutical Group Co's value of 10.61 is 173.5% above this benchmark. Historically, Yabao Pharmaceutical Group Co's own Altman Z2-Score has ranged from 2.67 to 11.03 over the past decade. While the company's 10-year median is 4.62 vs. the industry median of 3.88, Yabao Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Drug Manufacturers company?
The median Altman Z2-Score among Drug Manufacturers companies is 3.88, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yabao Pharmaceutical Group Co's current Altman Z2-Score of 10.61 is 173.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Yabao Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Altman Z2-Score is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yabao Pharmaceutical Group Co's current Altman Z2-Score is 10.61, which is 130% above median its own 10-year median of 4.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yabao Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co (SHSE:600351) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥5.53, compared to a current price of ¥6.56 — trading 18.6% above its estimated fair value. The current Altman Z2-Score is 10.61, which is 130% above median its 10-year median of 4.62 and 173.5% above the Drug Manufacturers industry median of 3.88. Yabao Pharmaceutical Group Co's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Yabao Pharmaceutical Group Co (SHSE:600351), the current Altman Z2-Score is 10.61 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Yabao Pharmaceutical Group Co (SHSE:600351) Overvalued in 2026?
Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥6.56 is trading 18.6% above its estimated GF Value™ of ¥5.53.
GuruFocus considers Yabao Pharmaceutical Group Co to be Modestly Overvalued.
Key valuation signals for SHSE:600351:
Altman Z2-Score: 10.61 (130% above median its 10-year median of 4.62)
GF Value™: ¥5.53 vs. price of ¥6.56 (18.6% above fair value)
Industry Position: 173.5% above the Drug Manufacturers median (#123 of 997)
No single metric tells the full story. See the SHSE:600351 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Yabao Pharmaceutical Group Co Business Description
Yabao Pharmaceutical Group Co Ltd is engaged in the manufacture and operation of western and Chinese medicines, APIs, health care products, packing materials for medicine, and also engages in the planting and processing of medicinal herbs.
70GF Score
Get the complete analysis for SHSE:600351
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600351 has been successfully added to your 
